Tech Company Financing Transactions
KAI Pharmaceuticals Funding Round
Skyline Ventures, Delphi Ventures and Intersouth Partners invested in a $17 million Series A capital raise for KAI Pharmaceuticals. The funding round was announced by the company on 12/3/2003.
Transaction Overview
Company Name
Announced On
12/3/2003
Transaction Type
Venture Equity
Amount
$17,000,000
Round
Series A
Investors
Proceeds Purpose
This successful financing positions KAI to emerge as one of the most exciting new biotechnology companies.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
270 Littlefield Avenue
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
KAI Pharmaceuticals is a biology-based product-driven pharmaceutical company developing a new class of therapeutics targeting cell-signaling enzymes that affect numerous disease pathways. The company is leveraging its leadership position in protein kinase C (PKC), an important and validated family of kinases, to rapidly advance product candidates into human clinical trials.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steven James
Chief Medical Officer
Gregory Bell
VP - Product Management
Susan Wilson
VP - R & D
Randolph Johnson
Browse more venture capital transactions:
Prev: 12/3/2003: PanGo Networks venture capital transaction
Next: 12/4/2003: Jamdat Mobile venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs